Company Description
Silo Pharma Inc. operates as a developmental stage biopharmaceutical company.
The company is developing therapeutics that address underserved conditions, including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases.
It focuses on developing traditional therapies and psychedelic treatments in formulations and drug delivery systems.
The company’s lead program, SPC-15, is an intranasal treatment targeting PTSD and stress-induced anxiety disorders.
It is also developing SP-26, a time-release ketamine-loaded implant for fibromyalgia and chronic pain relief.
In addition, the company’s two preclinical programs comprise SPC-14, an intranasal compound for the treatment of Alzheimer’s disease, and SPU-16, a CNS-homing peptide targeting multiple sclerosis (MS).
The company’s research and development programs are conducted through collaborations with Columbia University and the University of Maryland, Baltimore.
The company was formerly known as Uppercut Brands, Inc. and changed its name to Silo Pharma, Inc. in September 2020.
Silo Pharma, Inc. was incorporated in 2010 and is based in Sarasota, Florida.
| Country | United States |
| Founded | 2010 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 3 |
| CEO | Eric Weisblum |
Contact Details
Address: 677 N. Washington Blvd Sarasota, Florida 34236 United States | |
| Phone | (718) 400-9031 |
| Website | silopharma.com |
Stock Details
| Ticker Symbol | SILO |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001514183 |
| CUSIP Number | 82711P102 |
| ISIN Number | US82711P2011 |
| Employer ID | 46-2137136 |
| SIC Code | 2300 |
Key Executives
| Name | Position |
|---|---|
| Eric Weisblum | Chairman, President and Chief Executive Officer |
| Daniel E. Ryweck | Chief Financial Officer |
| Dr. James S. Kuo M.B.A., M.D. | Vice President of Research and Development |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jul 17, 2024 | S-1 | General form for registration of securities under the Securities Act of 1933 |
| Jul 8, 2024 | 8-K | Current Report |
| Jun 27, 2024 | 8-K | Current Report |
| Jun 13, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Jun 11, 2024 | D | Notice of Exempt Offering of Securities |
| Jun 6, 2024 | 8-K | Current Report |
| Jun 6, 2024 | 424B5 | Filing |
| Jun 4, 2024 | 8-K | Current Report |
| May 13, 2024 | 10-Q | Quarterly Report |
| Apr 5, 2024 | 8-K | Current Report |